Oral vs Topical Hair Loss Treatment: What the Trials Actually Show

In short: this is not a choice between a strong treatment and a weak one. It is a choice between two ways of delivering the same medicine, and they differ mainly in how much of it reaches the rest of your body. In a phase III randomised trial of 458 men, topical finasteride increased target-area hair count by an adjusted mean of 20.2 hairs at 24 weeks against 6.7 for placebo — a result the investigators described as numerically similar to oral finasteride — while peak plasma concentrations were more than a hundred times lower and the fall in serum DHT was 34.5% against 55.6% (PubMed 34634163). For minoxidil, a 2025 meta-analysis of four randomised trials found no difference between oral and topical in hair density or hair diameter, but roughly double the rate of unwanted body hair growth on the oral route (PubMed 39425514). In practice the decision is almost never made on efficacy. It is made on your medical background, which side effects you mind most, and what you will realistically keep doing every day for years.

Once a man has decided to treat hair loss, the next question is always the same one: a pill, or something you rub on? It is also the question that is hardest to get a straight answer to, for two reasons. Most of the pages that answer it are published by a company that sells exactly one of the two options. The rest are forum threads.

So start with the part that gets skipped: in most cases these are not two different treatments. They are two routes of administration for the same molecule. Not a strong version and a gentle version, and not two competing philosophies — two ways of getting the same drug to the hair follicle. Everything else follows from that single difference.

What is the actual difference between oral and topical?

An oral treatment is absorbed through the gut, passes through the liver and circulates through the bloodstream to the whole body — including, on the way, the scalp. A topical treatment is applied to the skin and reaches the follicle from above. Some of it still enters the bloodstream, but far less.

Two opposite consequences follow. The oral route reaches every follicle on the scalp evenly, with no dependence on where your hand went — but it also reaches every other tissue that did not ask for it. The topical route concentrates the drug where it is meant to act, but depends entirely on your applying it, correctly, every day.

What do the trials show for finasteride — pill versus applied?

This one has a genuinely good dataset behind it. A phase III, randomised, double-blind, double-dummy trial ran across 45 sites in Europe and enrolled 458 men with androgenetic alopecia, comparing a topical finasteride spray against placebo and measuring systemic exposure against the oral form (PubMed 34634163).

The primary endpoint was change in target-area hair count at 24 weeks. Topical finasteride produced an adjusted mean increase of 20.2 hairs against 6.7 for placebo, and the investigators reported the result as numerically similar to oral finasteride. Adverse-event rates and reasons for discontinuation did not differ meaningfully from placebo, and no serious adverse event was treatment-related.

But the number that matters most in this comparison is the exposure figure. Maximum plasma concentrations of finasteride were more than a hundred times lower with the topical formulation, and the mean reduction in serum DHT was 34.5% with topical against 55.6% with oral.

Why does that matter? Because most of the side effects men worry about with this drug are attributed to the systemic drop in DHT rather than to anything happening on the scalp. The trial was not designed to prove fewer sexual side effects — it measured exposure, and reasoned from it that systemic reactions were less likely. That is a meaningful distinction and worth holding onto: it is a lower theoretical risk, not a guarantee. We cover the side-effect question itself in more depth in reducing finasteride side effects.

There is also a practical caveat. Topical finasteride is not licensed as a separate product in every market, and availability varies by country. That is a question for the physician assessing your case, not something to conclude from a US or UK page.

And for minoxidil — tablet or solution?

Here the framing is reversed. The topical solution is the established, licensed form, and low-dose oral minoxidil is an off-label use that has expanded considerably over the last decade.

A meta-analysis published in the International Journal of Dermatology pooled four randomised trials covering 279 patients with follow-up of 24 to 39 weeks. It found no significant difference in hair density (SMD 0.02; 95% CI −0.25 to 0.29) and none in hair diameter (SMD −0.25; 95% CI −0.75 to 0.26). On efficacy, the two routes came out level (PubMed 39425514). A separate randomised trial in 65 patients comparing 5% topical solution against 1 mg daily oral minoxidil over six months reached the same conclusion: both groups improved significantly and the difference between them was not significant (PubMed 38031516).

The meta-analysis did find one clear difference, and it is the one that matters day to day — hypertrichosis, unwanted hair growth elsewhere on the body, was roughly twice as common on the oral route (RR 2.01; 95% CI 1.18–3.41). There was no significant difference between the groups in low blood pressure.

On the broader safety question there is a larger dataset. A multicentre study followed 1,404 patients treated with low-dose oral minoxidil for at least three months. Hypertrichosis occurred in 15.1%, leading to withdrawal in 0.5%. Systemic effects were uncommon: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%. In total 1.7% stopped treatment because of an adverse effect, and no life-threatening events were observed (PubMed 33639244). It is a retrospective study without a control group, and should be read as such.

So why would anyone choose the tablet?

Three practical reasons, and none of them is about potency.

The first is adherence. Applying a solution correctly, once or twice a day, to a dry scalp, for years, is a bigger ask than it sounds. A treatment you do not take consistently is not a gentler treatment — it is not a treatment.

The second is the skin itself. Minoxidil solutions contain solvents that can irritate, and some people cannot tolerate the itching, the flaking, or what the solution does to hair texture after application. Lifestyle matters too: if you train in the morning or wear a head covering at work, the drying window is a real obstacle.

The third is biological and the least widely known. Minoxidil is a prodrug — it has to be activated by an enzyme in the follicle to work at all. The activity of that enzyme varies between people, and follicular sulfotransferase activity has been studied as a possible predictor of response to topical minoxidil (PubMed 35950120). This is not a test used routinely in clinic, but it is a plausible explanation for why some people respond poorly to the applied form.

Oral versus topical, side by side

	Oral (tablet)	Topical (applied)
How it reaches the follicle	Via the bloodstream, evenly across the whole scalp	Through the skin, only where it is applied
Systemic exposure	Full	Substantially lower — for finasteride, peak plasma concentration more than 100× lower (PubMed 34634163)
Efficacy in trials	The long-established reference point	Finasteride: numerically similar to oral (PubMed 34634163). Minoxidil: no significant difference (PubMed 39425514)
Effect on serum DHT (finasteride)	−55.6%	−34.5% (PubMed 34634163)
Most common side effect	Minoxidil: hypertrichosis, 15.1% (PubMed 33639244)	Skin irritation, flaking, changed hair texture
Unwanted body hair	Roughly twice as common (RR 2.01; PubMed 39425514)	Less common
Depends on daily routine	Low — one action per day	High — correct application, dry scalp, consistently
Often suits	Men who will not keep up with application, who get skin irritation, or who did not respond to topical	Men who want to minimise systemic exposure and who have a settled daily routine
Identical for both	Prescription and medical assessment required; the effect is maintained only while treatment continues

Can the two be combined?

Yes, and it is common — but combining is a clinical decision, not a strategy of taking everything just in case. A single-blind study in 164 men comparing a combined topical finasteride 0.25% with minoxidil 5% against minoxidil 5% alone reported a higher response rate in the combination group at 12 weeks (86.7% against 69.1%; P=0.006) (PubMed 39496123). That is one study, single-blind, with short follow-up. It points in a direction; it does not settle the question.

The clinical principle is that every component should be there for a reason and there should be a way of knowing what is working. Start three things in the same week and you cannot tell which one produced the improvement or which one produced the irritation — and in that situation the natural instinct is to stop everything.

What actually decides it?

In a consultation this rarely opens with which one works better. It opens with duller questions: what is your medical background and what else are you taking; are you planning a pregnancy with a partner in the household; do you have an active scalp condition; and what is the realistic likelihood that you will apply something to your head every day for the next three years. Our overview of treatments for hair loss covers how this fits alongside PRP, laser and surgical options too.

One more thing is worth knowing in advance: on either route, the first months can involve a temporary increase in shedding. It is expected and is not a sign of failure. We explain it in shedding when starting treatment. And if you have not yet decided whether to treat at all, that is the prior decision — it is covered in when to start hair loss treatment.

The bottom line

The oral-versus-topical question is usually asked as though it has one correct answer. It does not, and that is not a dodge. On the efficacy endpoints measured in controlled trials, the two routes are closer together than most of the internet suggests. What genuinely differs is the collateral cost: how much of the drug reaches tissues that did not need it, and how much daily effort it demands of you. So the useful question is not "which is stronger" but "which will I actually keep doing, and what does my body prefer to be exposed to in the meantime". That is answerable only in an assessment that knows your history — not on a comparison page published by a company that sells one of the two answers. You can read about both routes and how the assessment works on our treatment page.

Frequently asked questions

Which is more effective, oral or topical?

In the controlled trials that compared them, the gap was small. For finasteride, a phase III trial in 458 men found a mean increase of 20.2 hairs with the topical form against 6.7 with placebo, a result described as numerically similar to the oral form (PubMed 34634163). For minoxidil, a meta-analysis of four randomised trials found no significant difference in hair density or diameter (PubMed 39425514). The practical difference is in systemic exposure and adherence, not in potency.

If topical is safer, why isn't everyone prescribed it?

Several reasons. Availability of licensed topical finasteride varies by country; some people get skin irritation or simply do not keep up with daily application; and the long-term dataset for the oral form has accumulated over decades. A physician weighs all of that against your individual medical background.

Is oral minoxidil dangerous?

In a multicentre study of 1,404 patients on low-dose oral minoxidil, the most frequent adverse effect was hypertrichosis at 15.1%. Systemic effects were uncommon — lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9% — and 1.7% discontinued because of an adverse effect, with no life-threatening events reported (PubMed 33639244). It was a retrospective study without a control group, and this use requires medical supervision.

How long before I can tell whether it is working, on either route?

Months, not weeks. The trials cited here measured outcomes at 24 weeks to a year. A meaningful assessment of response is usually not made before four to six months, and the early months may look worse because of temporary shedding.

Can I switch from one route to the other?

Yes, and it is common — usually when the current route is not tolerated or is not actually being done. The switch should be made with medical guidance rather than by stopping one and starting the other on your own without establishing why the first did not work.

Do both routes require a prescription in Israel?

Yes. Both are prescription-only in Israel and are dispensed after assessment by a physician licensed in Israel. That assessment is not a formality — it is also what establishes whether your hair loss is androgenetic alopecia in the first place.

For more on gever's editorial standards and clinical team, see our about page.

This page provides general medical information and is not medical advice, a diagnosis, or a substitute for individual medical assessment. Do not start, change or stop any prescription treatment without consulting a licensed physician. The medicines discussed here are prescription-only in Israel.

Sources: Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol 2022;36(2):286-294 — PubMed 34634163 · Sobral MVS, Moreira JLML, Rodrigues LK, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol 2025;64(3):479-484 — PubMed 39425514 · Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol 2021;84(6):1644-1651 — PubMed 33639244 · Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. J Cosmet Dermatol 2024;23(3):949-957 — PubMed 38031516 · Asad N, Naseer M, Ghafoor R. Efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in treatment of male pattern androgenic alopecia. J Drugs Dermatol 2024;23(11):1003-1008 — PubMed 39496123 · Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatol Alergol 2022 — PubMed 35950120 · Israel Ministry of Health drug registry and patient leaflets: israeldrugs.health.gov.il